Alba Brandes
Alba Brandes
Azienda USL-Irccs Bologna
Verified email at ausl.bologna.it
TitleCited byYear
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ...
New England Journal of Medicine 352 (10), 987-996, 2005
134412005
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the …
R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJB Taphoorn, ...
The lancet oncology 10 (5), 459-466, 2009
46522009
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma
OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ...
New England Journal of Medicine 370 (8), 709-722, 2014
13422014
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
MJ van den Bent, AA Brandes, MJB Taphoorn, JM Kros, ...
Journal of clinical oncology 31 (3), 344-350, 2012
7392012
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and …
MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ...
Journal of Clinical Oncology 24 (18), 2715-22, 2006
7202006
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ...
Journal of Clinical Oncology 26 (13), 2192-2197, 2008
6722008
European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of …
R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ...
Lancet Oncol 10 (5), 459-466, 2009
6112009
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ...
Nature Reviews Neurology 6 (1), 39, 2010
5612010
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre …
R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ...
The lancet oncology 15 (10), 1100-1108, 2014
4872014
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
RO Mirimanoff, T Gorlia, W Mason, MJ Van den Bent, RD Kortmann, ...
J Clin Oncol 24 (16), 2563-2569, 2006
4772006
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ...
Journal of Clinical Oncology 27 (8), 1268, 2009
4632009
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3
T Gorlia, MJ van den Bent, ME Hegi, RO Mirimanoff, M Weller, ...
The lancet oncology 9 (1), 29-38, 2008
4552008
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ...
The Lancet 374 (9700), 1512-1520, 2009
4452009
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of …
MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ...
Clinical Cancer Research 16 (5), 1597-1604, 2010
3872010
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group …
MJ van den Bent, HJ Dubbink, M Sanson, CR van der Lee-Haarloo, ...
Journal of Clinical Oncology 27 (35), 5881, 2009
2502009
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
M Weller, T Gorlia, JG Cairncross, MJ Van Den Bent, W Mason, ...
Neurology 77 (12), 1156-1164, 2011
2442011
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
AA Brandes, A Tosoni, G Cavallo, R Bertorelle, V Gioia, E Franceschi, ...
British journal of cancer 95 (9), 1155, 2006
2392006
Short-course radiation plus temozolomide in elderly patients with glioblastoma
JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ...
New England Journal of Medicine 376 (11), 1027-1037, 2017
2322017
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology
AA Brandes, A Tosoni, F Spagnolli, G Frezza, M Leonardi, F Calbucci, ...
Neuro-oncology 10 (3), 361-367, 2008
2272008
Epidemiology of glial and non-glial brain tumours in Europe
E Crocetti, A Trama, C Stiller, A Caldarella, R Soffietti, J Jaal, DC Weber, ...
European journal of cancer 48 (10), 1532-1542, 2012
2242012
The system can't perform the operation now. Try again later.
Articles 1–20